NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. (NBY)

Market Closed
12 Dec, 20:00
AMEX AMEX
$
2. 80
-0.01
-0.36%
$
6.13M Market Cap
- P/E Ratio
1% Div Yield
792,804 Volume
- Eps
$ 2.81
Previous Close
Day Range
2.55 3
Year Range
0.46 4.44
Want to track NBY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NBY closed yesterday lower at $2.8, a decrease of 0.36% from Thursday's close, completing a monthly increase of 164.15% or $1.74. Over the past 12 months, NBY stock gained 372.89%.
NBY is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0.21%. On average, the company has surpassed earnings expectations by 0.14%, based on the last three reports.
NovaBay Pharmaceuticals, Inc. has completed 3 stock splits, with the recent split occurring on May 31, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on AMEX (USD).

NBY Chart

Similar

Actinium Pharmaceuticals Inc.
$ 1.5
+3.79%
Maia Biotechnology Inc.
$ 1.36
-16.77%
IGC
IGC Pharma Inc.
$ 0.35
+6.1%
Nanoviricides Inc.
$ 1.25
-3.85%
Neuraxis Inc.
$ 2.65
+0.76%
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's Why

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 11 months ago
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

Seekingalpha | 1 year ago
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?

Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?

NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.

Investorplace | 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) FAQ

What is the stock price today?

The current price is $2.80.

On which exchange is it traded?

NovaBay Pharmaceuticals, Inc. is listed on AMEX.

What is its stock symbol?

The ticker symbol is NBY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1%.

What is its market cap?

As of today, the market cap is 6.13M.

Has NovaBay Pharmaceuticals, Inc. ever had a stock split?

NovaBay Pharmaceuticals, Inc. had 3 splits and the recent split was on May 31, 2024.

NovaBay Pharmaceuticals, Inc. Profile

Biotechnology Industry
Healthcare Sector
Michael Kazley CEO
AMEX Exchange
66987P201 CUSIP
US Country
13 Employees
30 Sep 2025 Last Dividend
31 May 2024 Last Split
- IPO Date

Overview

NovaBay Pharmaceuticals, Inc. is a healthcare company engaged in the development and commercialization of eyecare and wound care products across the United States and internationally. Known for its innovative approach towards effective healthcare solutions, the company provides a range of products targeted at improving ocular health and managing wounds. Initially named NovaCal Pharmaceuticals, Inc., it underwent a name change to NovaBay Pharmaceuticals, Inc. in February 2007. Since its incorporation in 2000, the company has been dedicated to offering products that meet the needs of patients, leveraging advanced technology and research to create effective solutions. Headquartered in Emeryville, California, NovaBay Pharmaceuticals continues to expand its portfolio and market presence, reaching a broader audience through both its web stores and various third-party online retailers and distribution partners.

Products and Services

  • Avenova Spray - A specialized solution designed for the removal of foreign materials, including microorganisms and debris from the skin around the eye, particularly the eyelid. This product aims to maintain optimal ocular hygiene and health.
  • Avenova Eye Health Support - Antioxidant-rich oral supplements developed to support overall eye health. These supplements are formulated to provide nutritional support to the eyes.
  • Avenova Lubricating Eye Drops - Engineered for instant relief, these eye drops are designed to moisturize and soothe dry eyes, providing users with immediate comfort.
  • NovaWipes by Avenova - Soft, absorbent wipes intended for the gentle cleansing of the eyelids and lashes, complementing the routine use of Avenova Spray to ensure a more comprehensive ocular hygiene regimen.
  • Avenova WarmEye Compress - A soothing solution for eyes, this compress is designed to provide warmth, helping to relieve discomfort from conditions such as dry eyes or meibomian gland dysfunction.
  • i-Chek by Avenova - An innovative tool for monitoring physical eyelid health, offering users a means to regularly check their eyelid condition and detect potential issues early on.
  • Wound Care Products - Under the brands NeutroPhase and PhaseOne, NovaBay Pharmaceuticals provides products for wound care, including solutions for cleansing and irrigation as part of surgical procedures, and for treating wounds, burns, ulcers, and other injuries. These products are crafted to aid in the healing process, ensuring effective wound management.

Contact Information

Address: 2000 Powell Street
Phone: 510 899 8800